Vous n'êtes pas encore inscrit ?
Inscription
Novasep will produce the active substance of the vaccine in its Belgian facilities
Lyon, France, June 15th, 2020–Novasep, a French company and European leader in the production of viral vectors, announces that it has signed a partnership with the biopharmaceutical company AstraZeneca for the production of the Oxford University vaccine to prevent COVID-19 infection.This partnership follows the agreement between AstraZeneca and the Inclusive Alliance for Vaccines (IAV), whose members are France, Germany, Italy and the Netherlands, to supply the Oxford University’s COVID-19 vaccine for the year 2021 for Europe.
Novasep brings to AstraZeneca more than 20 years of expertise in viral vector production. Novasep’s investment strategy in the large-scale production of biopharmaceutical products for immunotherapy and gene therapy enables Novasep to support the Alliance for the production of the vaccine active substance in Europe.
The production operations will be carried out at Novasep’s Belgian site in Seneffe. Furthermore, the biopharmaceutical ecosystem in the region allows Novasep to rapidly mobilize the additional human resources needed to achieve this project. Novasep will dedicate specific production areas and resources to this project. In parallel, Novasep will maintain its usual production capacities and continue to develop its activities in the field of viral vectors.
Michel Spagnol comments: “It is a great honour and pride for our teams in France and Belgium to contribute on a European scale to the fight against this pandemic. This confirms the increasing trends towards biopharmaceuticals and validates the strategic investment choices that we have been making in the production of viral vectors for several years with the support of our board. We thank AstraZeneca for its confidence in our expertise and industrial capacity. We look forward to meeting one of the major challenges of this decade“.
About Novasep
Novasep provides cost-effective and sustainable manufacturing solutions for the life sciences industries.With 20 years’ experience in the development and manufacturing of biomolecules, Novasep offers a full range of CDMO services for :
-Viral vectors (AAV, Adenovirus, Lentivirus, HSV, VSV, VEEV…) for cell and gene therapy, immunotherapy and vaccination, from process development to cGMP production
-Fill & Finish services for viral vectors, attenuated and live viruses, mAbs, plasmids and other biologics, from formulation to packaging.
As part of its growth strategy Rise-2, Novasep recently unveiled a new facility, Senrise-IV, dedicated to the commercial production of viral vectors which has been completed last year by Senefill, a new Fill & Finish commercial facility for aseptic operations. Both facilities located in Seneffe, Belgium, will contribute to the success of biopharmaceuticalsprojects.
